Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Chimera Bio Wins $7.5 Million Asia Award for Novel CAR-T Technology

publication date: Apr 28, 2022

Chimera Bioengineering of South San Francisco has won the Asian Fund for Cancer Research 2021 BRACE Award for its CAR-T research in cancers important to China patients. The BRACE award includes a $7.5 million prize. Chimera’s GOLD platform reprograms RNA gene regulation circuits to alter chimeric antigen receptors on T cells. The company engineers CAR-T cell therapies that weaken tumor microenvironments, increasing the efficacy of the CAR-T medicinal payload. BRACE stands for Bridging Research from Academic to Cancer Entrepreneurship. Chimera develops CAR-T therapies for solid tumor cancers. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China